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Abstract
Background: The transcription factors Elk1 and serum response factor (SRF) are central regulators of cell cycle and
phenotype in various cell types. Elk1 is activated by phosphorylation (serine-383), while activation of SRF requires its co-
factor, myocardin. Activation of Elk1 and SRF results in binding to specific DNA sequences in promoter regions, and may be
induced by adrenergic receptor activation in different organs.
Objective: To examine the effects of adrenergic stimulation on Elk1 and SRF in the human prostate and the ability of the
highly selective a1A-adrenoceptor antagonist, silodosin, on transcription factor activation.
Methods: Prostate tissue was obtained from patients undergoing radical prostatectomy. Expression of Elk1, SRF, and
myocardin was estimated by Western blot and immunohistochemistry. Colocalizations were studied by double
immunofluorescence staining. Noradrenaline- (NA-) and phenylephrine- (PE-) induced phosphorylation of Elk1 was
assessed by Western blot analysis using a phospho-specific antibody. NA-induced activation of Elk1 and SRF was
investigated by electrophoretic mobility shift assay (EMSA).
Results: Immunoreactivity for Elk1, SRF, and myocardin was observed in stromal cells of tissues from each patient. In
fluorescence stainings, SRF colocalized with myocardin and a-smooth muscle actin (aSMA). Stimulation of prostate tissues
with PE (10 mM) or NA (30 mM) increased the phosphorylation of Elk1 at serine-383. NA-induced Elk1 activation was
confirmed by EMSA, where a NA-induced binding of Elk1 to the DNA sequence TTTGCAAAATGCAGGAATTGTTTTCACAGT
was observed. Similarly, NA caused SRF binding to the SRF-specific DNA sequence CCATATTAGGCCATATTAGG. Application
of silodosin (3 mM) to prostate tissues reduced the activity of Elk1 and SRF in NA-stimulated tissues.
Conclusions: Silodosin blocks the activation of the two transcription factors, Elk1 and SRF, which is induced by
noradrenaline in the human prostate. A role of a1-adrenoceptors beyond smooth muscle contraction may be considered,
which includes a function in transcriptional regulation.
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Introduction
Male lower urinary tract symptoms (LUTS) can be caused by
benign prostate enlargement (BPE) and consequent benign
prostate obstruction (BPO) [1,2,3]. Prostate enlargement and
smooth muscle tone have for decades been regarded as separate
factors contributing to LUTS in patients with BPO (‘‘static’’ and
‘‘dynamic’’ component of obstruction) [2,4], and medical treat-
ment of LUTS is directed at both components. Since the dynamic
component has been shown to be caused by an increased a1-
adrenoceptor- (AR-) mediated prostate smooth muscle tone [5],
treatment with a1-adrenoceptor antagonists is a logical first-line
therapy [1,2,3,5]. Recently, the novel a1-AR antagonist silodosin
has been introduced in many countries [6].
However, functions of prostate a1-ARs beyond contraction
have been suggested, including a role in stromal growth and
prostate hyperplasia [1]. Growth and hyperplastic changes always
require activation of different transcription factors. In smooth
muscle cells outside the lower urinary tract, Elk1 and SRF are
critically involved in cell cycle and growth [7,8,9,10,11]. Although
a1-ARs, together with other factors, have been proposed to be
involved in prostate growth, a regulation of Elk1 or SRF by these
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receptors has, to the best of our knowledge, not been considered to
date.
In the present investigation, we have studied the adrenergic
regulation of Elk1 and SRF transcription factors in the human
prostate and its modulation by the highly selective a1A-AR
antagonist, silodosin.
Materials and Methods
Human Prostate Tissue
Human prostate tissue was obtained from patients undergoing
radical prostatectomy for prostate cancer, but without previous
TURP (n= 60). Procedures were carried out in accordance with
the Declaration of Helsinki of the World Medical Association, and
has been approved by the ethics committee of the Ludwig-
Maximilians University, Munich, Germany. According to the
approvement of the ethics committee, informed consent from
patients was not required, because all samples were collected and
analyzed anonymously. All samples were taken from the
periurethral zone, and did not exhibit histological signs of
neoplasia, cancer, or inflammation, as assessed by a dedicated
pathologist. Tissues were either directly shock frozen with liquid
nitrogen, or stimulated in vitro as described below.
In vitro Stimulation
For in vitro stimulation, tissue specimens were prepared as small
strips (2–3 mm61 mm) and allocated to dishes of a 6-well plate
containing Custodiol solution. During experiments, plates were
kept at 37uC under continuous shaking. For stimulation with
noradrenaline (NA) or phenylephrine (PE), 10 mM stock solution
was added in required intervals and volumes. Agonist concentra-
tions used in our study (30 mM NA, 10 mM PE) are known to
induce maximum contraction and activation of intracellular
signaling pathways in human prostate tissue [12,13]. To avoid
effects due to different stimulation or incubation periods, samples
were stimulated backwards, i. e. by addition of agonists 20 min,
10 min, and 5 min before the end of the experiment. Finally,
stimulated and unstimulated samples were simultaneously shock
frozen in liquid nitrogen. Therefore, all samples were exposed to
the experimental conditions for identical total time periods. In
separate experiments, silodosin (3 mM) or solvent (3 ml dimethyl-
sulfoxide, DMSO) were added 15 min before application of NA
(30 mM) to two of three samples. Again, all samples were exposed
to the experimental conditions for identical total time periods.
Samples were stored at 280uC until Western blot analysis was
performed.
Western Blot Analysis
Frozen tissues were homogenized and analyzed by Western blot
analysis as described recently [14] using the following antibodies:
monoclonal mouse anti phospho-Elk1 (serine-383) (B-4), mono-
clonal mouse anti Elk1 (3H6D12), monoclonal mouse anti SRF
(A-11), polyclonal rabbit anti myocardin, monoclonal mouse anti
a-smooth muscle actin (aSMA), or monoclonal mouse anti b-actin
(C4) (all from Santa Cruz Biotechnology, Santa Cruz, CA, USA).
Blots were developed with enhanced chemiluminescence (ECL)
using ECL Hyperfilm (GE Healthcare, Freiburg, Germany).
Intensities of resulting bands were quantified using Image J
(NIH, Bethesda, Maryland, USA). In experiments for expression
analysis, tissues from eight patients were assessed in each gel. In
stimulation experiments, samples without and with agonist were
semiquantitatively compared: samples without stimulation were set
to 100%, and stimulated samples from the same prostate were
expressed as % of unstimulated samples.
Figure 1. Elk1 expression in human prostate tissue. (A), (B) Peroxidase staining of prostate tissues for Elk1. (A) Cytosolic Elk1 immunoreactivity
in smooth muscle cells (smc). (B) Elk1-positive (Elk1+) and –negative (Elk12) nuclei. (C) Peroxidase staining of prostate tissue for phospho-Elk1, with
phospho-Elk-positive (pElk1+) nuclei. (D) Double fluorescence staining of human prostate tissue for Elk1 and aSMA. Yellow color in merged pictures
represents Elk1 expression in smooth muscle cells. Shown are representative pictures from stainings from tissues of n= 6 patients for each staining.
doi:10.1371/journal.pone.0050904.g001
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Immunohistochemistry
Sections (6–8 mm) from frozen tissues were stained by an
indirect immunoperoxidase technique, as described recently [14]
using the following antibodies: monoclonal mouse anti phospho-
Elk1 (serine-383) (B-4), monoclonal mouse anti Elk1 (3H6D12),
monoclonal mouse anti SRF (A-11), or polyclonal rabbit anti
myocardin (all from Santa Cruz Biotechnology, Santa Cruz, CA,
USA). Control stainings without primary antibodies did not yield
any immunoreactivity.
Immunofluorescence
Human prostate specimens were double labelled as described
recently [14] using the following antibodies: monoclonal mouse
anti Elk1 (3H6D12), monoclonal mouse anti SRF (A-11), poly-
clonal rabbit anti myocardin (all from Santa Cruz Biotechnology,
Santa Cruz, CA, USA), and rabbit polyclonal anti a-smooth
muscle actin (aSMA) (Thermo Scientific, Waltham, MA, USA).
Binding sites were visualized using Cy3 and Cy5 conjugated
secondary antibodies (goat anti mouse, AP124C, Millipore,
Billerica, MA, USA; goat anti rabbit, ab6564, Abcam, Cambridge,
UK). Nuclei were counterstained with DAPI (Invitrogen, Camar-
illo, CA, USA). Fluorescence was recorded with separate detectors.
Control stainings without primary antibodies did not yield any
signals.
EMSA
Activation of Elk1 and SRF was investigated by non-radioactive
electrophoretic mobility shift assays (EMSA), where binding of
transcription factors to biotin-labelled, specific DNA probes is
determined. Assays were performed using commercially available
kits (Affymetrix, Santa Clara, CA, USA) according to the
manufacturer’s instruction. In brief, stimulated and unstimulated
tissues were homogenized and subjected to protein determination.
Twenty mg of protein were incubated with biotin-labelled DNA
probe with the sequence TTTGCAAAATGCAG-
GAATTGTTTTCACAGT (5939) for Elk1, or CCATAT-
TAGGCCATATTAGG for SRF. After incubation, samples were
subjected to electrophoresis in native, non-denaturating acrylam-
ide gels (6%), and subsequently blotted on nylon membranes,
where detection for biotin was performed with peroxidase-coupled
streptavidin and ECL. Intensities of resulting bands were
quantified using Image J (NIH, Bethesda, Maryland, USA).
Correct experimental conditions were approved by application of
a negative control provided by the manufacturer.
Drugs and Solutions
Aqueous stock solutions for NA and the a1-AR agonist PE
(Sigma, St. Louis, MO, USA) (10 mM) were freshly prepared
before each experiment. Silodosin, a highly selective a1A-AR
Figure 2. SRF and myocardin expression in human prostate tissue. (A) Western blot analyses with prostate tissues from n= 8 patients,
showing the expression of SRF, myocardin, aSMA, and b-actin. (B) Peroxidase staining of prostate tissues for SRF and myocardin (representative
stainings of tissues from n= 6 patients). (C) Double fluorescence staining of prostate tissues for SRF and aSMA (representative stainings of tissues
from n= 6 patients). Yellow color in merged pictures represents SRF expression in smooth muscle cells. (D) Double fluorescence staining of prostate
tissues for SRF and myocardin (representative stainings of tissues from n=6 patients). Yellow color in merged pictures represents colocalization of
SRF and myocardin). In (C) and (D), examples for colocalization are indicated by arrows.
doi:10.1371/journal.pone.0050904.g002
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antagonist [6,15] was kindly provided by Recordati S. p. A.
(Milan, Italy). Silodosin was added as 10 mM stock solution in
DMSO, which was stored at 220uC.
Statistical Analysis
Data are presented as means6standard error of the mean
(SEM) with the indicated number (n) of experiments. Two-tailed
student t test was used for paired or unpaired observations. P
values ,0.05 were considered statistically significant.
Results
Elk1 Expression
After peroxidase staining with an Elk1 antibody, immunoreac-
tivity was observed in samples from each investigated patient
(n = 6). Imunoreactivity was observed in stromal cells, but not in
epithelial cells (Fig. 1A). Elk1 immunoreactivity was located to the
cytosol and nuclei (Fig. 1A,B). Similarly, peroxidase staining with
a phospho-specific Elk1 resulted in immunoreactivity in each
investigated prostate sample (n = 6 patients). Immunoreactivity for
phospho-Elk1 was observed in stromal cells, where it was located
to the cytosol and nuclei (Fig. 1C).
Fluorescence staining of prostate samples (n = 6 patients) with
antibodies for Elk1 or aSMA resulted in immunoreactivity in the
prostate stroma (Fig. 1D). In merged pictures, Elk1 and aSMA
showed discrete colocalization, as indicated by yellow color in the
prostate stroma after overlay (Fig. 1D).
SRF and Myocardin Expression
Western blot analysis for SRF revealed bands matching the
expected size (52 kDa), which were observed in prostate samples
from each investigated patient (n = 8) (Fig. 2A). Peroxidase staining
of prostate samples (n = 6 patients) using a SRF antibody resulted
in immunoreactivity in stromal cells, which was observed in each
investigated sample (Fig. 2B). Similarly, Western blot analysis for
myocardin revealed bands matching the expected size (102 kDa)
in prostate samples from each investigated patient (n = 8) (Fig. 2A).
Peroxidase staining of prostate samples (n = 6 patients) using
a myocardin antibody resulted in immunoreactivity in stromal
cells, which was observed in each investigated sample (Fig. 2B).
The smooth muscle marker, aSMA, and the housekeeping protein
and loading control, b-actin, was detectable by Western blot
analysis in samples of each investigated patient (n = 8) (Fig. 2A).
The content of aSMA and b-actin was similar between these
samples (Fig. 2A).
Double fluorescence staining of prostate samples (n = 6 patients)
with antibodies for SRF and aSMA resulted in immunoreactivity
in the prostate stroma (Fig. 2C). In merged pictures, SRF and
aSMA showed colocalization, as indicated by yellow color in the
prostate stroma after overlay (Fig. 2C). Similarly, fluorescence
staining of prostate samples (n = 6 patients) with a myocardin
antibody resulted in immunoreactivity in the prostate stroma
(Fig. 2D). Fluorescence for myocardin colocalized with immuno-
reactivity for SRF, as indicated by yellow color in merged pictures
(Fig. 2D).
Elk1 Phosphorylation by Adrenergic Stimulation
By Western blot analysis, phospho-Elk1 and total Elk1 were
detected with the expected molecular weight (45 kDa) in prostate
samples. Stimulation of prostate samples (n = 5 patients) with NA
(30 mM) caused Elk1 phosphorylation at serine-383, as indicated
by increased density of bands for phospho-Elk1 (Fig. 3A). NA-
Figure 3. Adrenergic Elk1 phosphorylation in human prostate tissue. Prostate tissue from each patient was allocated to four samples, which
were stimulated for indicated periods. Despite different stimulation periods, all samples were exposed for identical total periods to experimental
conditions to prevent agonist-unspecific effects. Phosphorylation state of Elk1 and total Elk1 content was assessed by Western blot analysis. In each
experiment, phospho-Elk1 and total Elk1 in unstimulated samples ( = 0 min) was set to 100%, and values for stimulated samples were referred to the
unstimulated sample. (A) Stimulation with NA (n= 5 patients). (B) stimulation with the a1-AR agonist PE (n = 11 patients). Shown are representative
Western blots, and densitometric quantification of all experiments (means6SEM).
doi:10.1371/journal.pone.0050904.g003
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induced Elk1 phosphorylation was observed 5, 10, and 20 min
after stimulation (Fig. 3A). The content of total Elk1 in these
samples remained unchanged, as shown by Western blot analyses
using a non-phospho-specific Elk1 antibody (Fig. 3A). Similarly,
stimulation of prostate samples (n = 11 patients) with PE (10 mM)
caused Elk1 phosphorylation at serine-383, which was observed 5,
10, and 20 min after stimulation (Fig. 3B). The content of total
Elk1 in these samples remained unchanged (Fig. 3B).
Elk1 and SRF Activation by NA
Stimulation of prostate tissues (n = 9 patients) with NA (30 mM)
increased the binding of Elk1 to the Elk1-specific DNA probe with
the sequence TTTGCAAAATGCAGGAATTGTTTTCA-
CAGT, indicating NA-induced Elk1 activation (Fig. 4A). Similar-
ly, stimulation of prostate tissues (n = 9 patients) with NA (30 mM)
induced SRF activation, as shown by increased binding of SRF to
the SRF-specific DNA probe with the sequence CCATAT-
TAGGCCATATTAGG after NA stimulation (Fig. 4B). NA-
induced activation of Elk1 and SRF was observed after 5, 10, and
20 min of stimulation (Fig. 4).
Inhibition of NA-induced Elk1 and SRF Activation by
Silodosin
Application of silodosin (3 mM) to prostate tissues (n = 6
patients) 15 min before addition of NA (30 mM, 15 min) reduced
the content of activated Elk1 in EMSA (Fig. 5A), and of
phosphorylated Elk1 in Western blot analysis (Fig. 5B). Similarly,
silodosin reduced the content of SRF in NA-stimulated samples
(n = 6 patients), as detected by EMSA (Fig. 6).
Discussion
The present results show that in the human prostate, a1-AR
stimulation with NA activates the two transcription factors, Elk1
and SRF, and that the selective a1A-AR antagonist, silodosin,
blocks this activation. To the best of our knowledge, this is the first
evidence that stimulation of a1-ARs causes activation of
transcription factors in human prostate smooth muscle.
Activation of transcription factors is mandatory for growth- and
differentiation-related processes, which are the basis for hyper-
plastic changes. Therefore, we assume that a1-AR-mediated Elk1
and SRF activation may be involved in prostate growth and
hyperplasia. Contraction and growth may both contribute to
BPO, but were regarded as separate phenomenons for decades
(‘‘dynamic’’ and ‘‘static component’’) [2,4]. a1-AR activation of
Elk1 and SRF may thus represent a connection linking adrenergic
contraction to growth/hyperplasia. Whether both factors act in
concert or separately in the prostate, may not be concluded from
our present findings. Detailed identification of Elk1 and SRF
function in the prostate require studies in genetically modified cell
cultures or animals. Specific pharmacological inhibitors for Elk1 or
SRF have not been developed to date. Therefore, this remains
a large issue, which may be adressed by separate studies.
Figure 4. NA-induced Elk1 and SRF activation in human prostate tissue. Prostate tissue from each patient was allocated to four samples,
which were stimulated for indicated periods. Despite different stimulation periods, all samples were exposed for identical total periods to
experimental conditions to prevent agonist-unspecific effects. Elk1 and SRF activities were asssessed by EMSA. Bands for active transcription factors
(bound to DNA probes) were identified using negative controls, and are indicated by arrows. In each experiment, Elk1 or SRF in unstimulated samples
( = 0 min) was set to 100%, and values for stimulated samples were referred to the unstimulated sample. (A) NA-induced Elk1 activation (n = 9
patients). (B) NA-induced SRF activation (n = 9 patients). Shown are representative experiments, and densitometric quantification of all experiments
(means6SEM).
doi:10.1371/journal.pone.0050904.g004
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Our study was performed in tissues from patients undergoing
radical prostatectomy. We used non-malignant tissue from the
periurethral zone, while most prostate tumors are located to the
peripheral zone [16,17]. Almost all patients undergoing radical
prostatectomy show prostate hyperplasia. Therefore, normal, non-
hyperplastic tissue was not available for our study, and our findings
Figure 5. Inhibition of NA-induced Elk1 activation by silodosin. Prostate tissue from each patient was allocated to three samples, which were
stimulated with NA (30 mM) for 15 min, or remained unstimulated. Silodosin (3 mM) or solvent (3 ml DMSO) were added 15 min before NA as
indicated. All samples were exposed for identical total periods to experimental conditions to prevent agonist-unspecific effects. In each experiment,
Elk1 in NA-stimulated samples without silodosin ( = DMSO) was set to 100%, and values for samples with silodosin were referred to that sample. (A)
Inhibition of Elk1 activity by silodosin in NA-stimulated prostate samples (n = 6 patients), detected by EMSA. (B) Inhibition of Elk1 phosphorylation by
silodosin in NA-stimulated prostate samples (n = 6 patients), assessed by Western blot analysis. Shown are representative experiments, and
densitometric quantification of all experiments (means6SEM).
doi:10.1371/journal.pone.0050904.g005
Elk1/SRF Activation by Prostate a1-adrenoceptors
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may represent the conditions in the hyperplastic prostate. Of note,
expression of the smooth muscle marker aSMA was detectable in
all investigated samples.
Elk1 is activated by phosphorylation at serine-383, resulting in
Elk1 binding to specific DNA sequences of promoter regions
[10,18]. These sequences are mimicked by biotin-labelled DNA
probes in EMSA, while the phosphorylation can be investigated
using phospho-specific antibodies. Using both techniques, we
observed Elk1 activation by PE and NA that could be counter-
acted by silodosin. Transcriptional regulation by transcription
factors requires their nuclear localization, so that Elk1 is recruited
from the cytosol to nuclei after its activation [10,18]. In our
immunohistochemical stainings, many smooth muscle cells showed
Elk1- and phospho-Elk1-positive nuclei. This supports the idea
that parts of the prostatic Elk1 population are active, and regulate
transcription under physiological conditions. However, we can not
exclude the contribution of non-adrenergic mediators to prostate
Elk1 activity besides a1-ARs. In cultured prostate cancer cells,
androgen receptors and growth factors activate Elk1 as well
[19,20,21].
In smooth muscle cells outside the lower urinary tract, Elk1-
dependent transcription has been related to proliferation, growth
and differentiation [8,9,10]. Elk1 was identified as an effector of
the extracellular signal regulated kinases (ERK1/2), which are
ubiquitous regulators of cell cycle [8,9,10,18]. Interestingly,
stimulation of a1-ARs in human prostate tissues or cultured
prostate smooth muscle cells results in activation of ERK1/2
[12,22]. Similar to non-malignant conditions, Elk1 activation in
prostate cancer cells is involved in proliferation and tumor growth
[20,23].
Using a SRF-specific EMSA, we observed that stimulation of
prostate a1-ARs activates SRF in addition to Elk1. Activation of
SRF requires the cofactor myocardin [7,11]. Expression of
myocardin and its colocalization with SRF in our prostate samples
was confirmed by double fluorescence stainings. In smooth muscle
cells of the cardiovascular system, SRF connects adrenergic
contraction with cellular differentiation and proliferation [7,11].
This link has been termed as ‘‘transcription-excitation coupling’’
[7,11]. By activation of SRF, adrenergic receptors are involved in
the regulation of smooth muscle cell phenotype [7,11]. Cells may
switch between a ‘‘contractile’’ or ‘‘synthetic’’ phenotype; each
phenotype being characterized by different contractility and
proliferation rate [7,11]. Our present findings suggest that
a similar, SRF-mediated coupling of contraction to cellular
differentiation may exist in human prostate smooth muscle.
It is widely accepted that a1-AR antagonists cause improvement
of symptoms by smooth muscle relaxation in the lower urinary
tract, including the prostate [1,2,3,5]. In addition to its role for
contraction, non-motoric functions mediated by prostate a1-ARs
have been previously assumed by different authors [1,4]. Studies
performed in animal models and cultured cells, but also clinical
data suggested an involvement of prostate a1-adrenoceptors in
prostate growth and hyperplasia [24,25]. Intervention of a1-
blockers into the cell cycle was observed in cultured prostate cells,
but also in patients receiving a1-AR antagonists
[26,27,28,29,30,31]. The latter was associated with reduced
growth and stromal regression [27,28,29,30,31]. However, sub-
stantial regression of prostate volume has not been demonstrated
during the widespread application of a1-AR antagonists. Conse-
quently, it has been proposed that a1-ARs act in concert with
hormones and growth factors, being just one of the factors within
a complex regulatory network that regulates prostate growth [12].
Nevertheless, a reduction of prostate volume was observed in
a clinical study using terazosin [32]. In contrast, therapy with
Figure 6. Inhibition of NA-induced SRF activation by silodosin. Prostate tissue from each patient was allocated to three samples, which were
stimulated with NA (30 mM) for 15 min, or remained unstimulated. Silodosin (3 mM) or solvent (3 ml DMSO) were added 15 min before NA as
indicated. All samples were exposed for identical total periods to experimental conditions to prevent agonist-unspecific effects. In each experiment,
SRF in NA-stimulated samples without silodosin ( =DMSO) was set to 100%, and values for samples with silodosin were referred to that sample.
Shown are representative experiments, and densitometric quantification of all experiments (n = 6 patients; means6SEM).
doi:10.1371/journal.pone.0050904.g006
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alfuzosin for three month did not reduce prostate volume [33], nor
did the long-term treatment in the MTOPS (doxazosin) or
COMBAT (tamsulosin) study [34,35]. It has been proposed that
further studies are required, as effects may be substance-specific or
depend on study conditions [33].
The effect of silodosin on prostate volume has not been
considered to date. Since the majority of the stromal a1-ARs are of
the a1A subtype [1], particularly in BPH, the present results were
not unexpected. Considering its high selectivity for a1A-ARs [15],
it cannot be excluded that the effects of silodosin may differ from
that of other a1-ARs antagonists. Therefore, further investigations
are required.
Conclusions
a1-AR-mediated activation of Elk1 and SRF may represent
a mechanism connecting prostate contraction and growth
(‘‘dynamic’’ and ‘‘static’’ components) to each other. The function
of prostate a1-ARs is not confined to smooth muscle contraction,
but also comprises regulation of transcriptional activity. Adrener-
gic Elk1 and SRF activation in the human prostate can be blocked
by silodosin. The translational value of this silodosin effect needs to
be confirmed by clinical studies.
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